A SPIN-OFF company founded by three University of Sydney and Sydney Local Health District academics has received $2.2m in backing from Australian biotech incubator Proto Axiom.
The first application focuses on oral insulin for people with type 1 diabetes.
The program is supported by a Medical Research Future Fund targeted translational research accelerator grant, and is in accredited manufacturing with Commonwealth Scientific and Industrial Research Organisation, prior to entering clinical trials in 2024.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Apr 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Apr 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
